Document is current
Any future updates will be listed below
-
Authors
Brooks-Warburton, Johanne
Modos, Dezso http://orcid.org/0000-0001-9412-6867
Sudhakar, Padhmanand
Madgwick, Matthew
Thomas, John P.
Bohar, Balazs
Fazekas, David
Zoufir, Azedine http://orcid.org/0000-0001-8501-5348
Kapuy, Orsolya
Szalay-Beko, Mate
Verstockt, Bram http://orcid.org/0000-0003-3898-7093
Hall, Lindsay J. http://orcid.org/0000-0001-8938-5709
Watson, Alastair http://orcid.org/0000-0003-3326-0426
Tremelling, Mark
Parkes, Miles http://orcid.org/0000-0002-6467-0631
Vermeire, Severine http://orcid.org/0000-0001-9942-3019
Bender, Andreas
Carding, Simon R.
Korcsmaros, Tamas http://orcid.org/0000-0003-1717-996X
- License Information
-
More Information
Article History
Received: 20 June 2019
Accepted: 6 April 2022
First Online: 28 April 2022
Competing interests
: J.B.W., T.K. and S.R.C. are named inventors on the granted patent PCT/GB2019/053128, INT.class: G16B 5/00. The patent was applied by the Earlahm Institute and Quadram Institute and it contains the iSNP workflow to create disease-specific networks from SNP data. J.B.W. received lecture fees from Falk Pharma and financial support for research from AbbVie. B.V. and S.V. received financial support for research from MSD, Abbvie, Janssen, Takeda and Pfizer; lecture fees from Abbott, Abbvie, Merck Sharpe & Dohme, Ferring Pharmaceuticals, Pfizer, Takeda, Galapagos/Gilead and UCB Pharma; consultancy fees from Pfizer, Ferring Pharmaceuticals, Shire Pharmaceuticals Group, Merck Sharpe & Dohme, Abbvie, Takeda, Prodigest, Celgene, Galapagos, Gilead, Arena Pharmaceuticals, Genentech/Roche, Abivax and AstraZeneca Pharmaceuticals. D.M. got consultancy fees from HEALX and IOTA Pharmaceuticals. The remaining authors declare no competing interests.
